INmune Bio Past Earnings Performance
Past criteria checks 0/6
INmune Bio's earnings have been declining at an average annual rate of -28.9%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 43.4% per year.
Key information
-28.9%
Earnings growth rate
-18.6%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 43.4% |
Return on equity | -101.8% |
Net Margin | -44,402.4% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
It's Unlikely That Shareholders Will Increase INmune Bio, Inc.'s (NASDAQ:INMB) Compensation By Much This Year
Jul 12Is INmune Bio (NASDAQ:INMB) Using Debt Sensibly?
Jan 19Is INmune Bio (NASDAQ:INMB) Using Debt In A Risky Way?
Sep 04Is INmune Bio (NASDAQ:INMB) Using Too Much Debt?
May 12Here's Why INmune Bio (NASDAQ:INMB) Can Manage Its Debt Despite Losing Money
Jan 16Here's Why INmune Bio (NASDAQ:INMB) Can Manage Its Debt Despite Losing Money
Jul 11INmune Bio: Possibly The Once In A Lifetime Dip
May 25INmune Bio: Speculative Biotech With 2 Solid Potential Approaches To Treating AD And Solid Tumors
Apr 05Is INmune Bio (NASDAQ:INMB) A Risky Investment?
Mar 25Is INmune Bio (NASDAQ:INMB) Using Too Much Debt?
Dec 02INmune Bio A No-Brainer Investment
Oct 13INmune Bio: High-Risk High-Reward Alzheimer's Play
Aug 18Our Bullish Take On INmune Bio's Drug Pipeline
Aug 12INmune Bio: Underfollowed AD Player With Very Bullish August Momentum
Jul 13Companies Like INmune Bio (NASDAQ:INMB) Are In A Position To Invest In Growth
Jun 25INmune enters $15M credit facility to fund purchase of Xencor option
Jun 14Revenue & Expenses Breakdown
How INmune Bio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 0 | -38 | 10 | 28 |
31 Mar 24 | 0 | -34 | 10 | 25 |
31 Dec 23 | 0 | -30 | 10 | 20 |
30 Sep 23 | 0 | -27 | 9 | 18 |
30 Jun 23 | 0 | -27 | 9 | 17 |
31 Mar 23 | 0 | -27 | 9 | 17 |
31 Dec 22 | 0 | -27 | 9 | 17 |
30 Sep 22 | 0 | -31 | 9 | 21 |
30 Jun 22 | 0 | -33 | 9 | 22 |
31 Mar 22 | 0 | -33 | 9 | 22 |
31 Dec 21 | 0 | -30 | 9 | 21 |
30 Sep 21 | 0 | -24 | 8 | 15 |
30 Jun 21 | 0 | -19 | 8 | 11 |
31 Mar 21 | 0 | -15 | 7 | 8 |
31 Dec 20 | 0 | -12 | 6 | 6 |
30 Sep 20 | 0 | -11 | 6 | 5 |
30 Jun 20 | 0 | -10 | 6 | 4 |
31 Mar 20 | 0 | -8 | 6 | 3 |
31 Dec 19 | 0 | -8 | 6 | 3 |
30 Sep 19 | 0 | -7 | 5 | 3 |
30 Jun 19 | 0 | -6 | 3 | 4 |
31 Mar 19 | 0 | -11 | 8 | 4 |
31 Dec 18 | 0 | -12 | 9 | 3 |
30 Sep 18 | 0 | -11 | 8 | 3 |
30 Jun 18 | 0 | -10 | 9 | 1 |
31 Mar 18 | 0 | -4 | 3 | 0 |
31 Dec 17 | 0 | -1 | 1 | 0 |
30 Sep 17 | 0 | -1 | 0 | 0 |
31 Dec 16 | 0 | 0 | 0 | 0 |
Quality Earnings: INMB is currently unprofitable.
Growing Profit Margin: INMB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: INMB is unprofitable, and losses have increased over the past 5 years at a rate of 28.9% per year.
Accelerating Growth: Unable to compare INMB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: INMB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.5%).
Return on Equity
High ROE: INMB has a negative Return on Equity (-101.79%), as it is currently unprofitable.